Hematopoietic Cell Transplantation and Novel Therapies in Hemophagocytic Lymphohistiocytosis

  • K. Scott Baker
  • Michael B. Jordan


Hematopoietic cell transplantation (HCT) is currently the only curative therapy for primary HLH. While HCT carries substantial risks for patients with HLH, HCT is essential for preventing future episodes of fatal HLH in patients with genetic predisposition to HLH. Survival with HCT has increased significantly in recent years with the adoption of reduced intensity conditioning (RIC) regimens. However, RIC treatment protocols carry their own distinct issues including the frequent development of mixed chimerism. Patients with HLH are also challenging due to the potential for recurrence of HLH post HCT. Novel therapies, including interferon neutralization and genetic therapies, may facilitate initial and definitive therapy for future patients with HLH.


Hematopoietic cell transplantation Reduced intensity conditioning Mixed chimerism Gene therapy 



Central nervous system


Graft-versus-host disease


Hematopoietic cell transplantation


Hemophagocytic lymphohistiocytosis


Myeloablative conditioning


Reduced intensity conditioning


Umbilical cord blood


Veno-occlusive disease


  1. 1.
    Fischer A, et al. Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosis. J Pediatr. 1986;108(2):267–70.CrossRefPubMedGoogle Scholar
  2. 2.
    Arico M, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia. 1996;10(2):197–203.PubMedGoogle Scholar
  3. 3.
    Baker KS, et al. Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation. Blood. 1997;89(10):3857–63.PubMedGoogle Scholar
  4. 4.
    Ohga S, et al. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatr Blood Cancer. 2010;54(2):299–306.PubMedGoogle Scholar
  5. 5.
    Sawada A, et al. Feasibility of reduced-intensity conditioning followed by unrelated cord blood transplantation for primary hemophagocytic lymphohistiocytosis: a nationwide retrospective analysis in Japan. Int J Hematol. 2013;98(2):223–30.CrossRefPubMedGoogle Scholar
  6. 6.
    Jabado N, et al. Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors. Blood. 1997;90(12):4743–8.PubMedGoogle Scholar
  7. 7.
    Imashuku S, et al. Allogeneic hematopoietic stem cell transplantation for patients with hemophagocytic syndrome (HPS) in Japan. Bone Marrow Transplant. 1999;23(6):569–72.CrossRefPubMedGoogle Scholar
  8. 8.
    Henter JI, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367–73.CrossRefPubMedGoogle Scholar
  9. 9.
    Baker KS, et al. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant. 2008;42(3):175–80.CrossRefPubMedGoogle Scholar
  10. 10.
    Horne A, et al. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol. 2005;129(5):622–30.CrossRefPubMedGoogle Scholar
  11. 11.
    Ouachee-Chardin M, et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics. 2006;117(4):e743–50.CrossRefPubMedGoogle Scholar
  12. 12.
    Cesaro S, et al. Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP). Haematologica. 2008;93(11):1694–701.CrossRefPubMedGoogle Scholar
  13. 13.
    Cooper N, et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood. 2006;107(3):1233–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Marsh RA, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010;116(26):5824–31.CrossRefPubMedGoogle Scholar
  15. 15.
    Marsh RA, et al. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Biol Blood Marrow Transplant. 2013;19(11):1625–31.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lehmberg K, et al. Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis. Haematologica. 2014;99(1):180–4.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Haines HL, et al. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases. Biol Blood Marrow Transplant. 2015;21(2):288–92.CrossRefPubMedGoogle Scholar
  18. 18.
    Hartz B, et al. The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. Blood. 2016;127(25):3281–90.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Jaiswal SR, et al. Hemophagocytic syndrome following haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Int J Hematol. 2016;103(2):234–42.CrossRefPubMedGoogle Scholar
  20. 20.
    Koyama M, et al. Encouraging results of low-dose etoposide in the treatment of early-onset hemophagocytic syndrome following allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2007;86(5):466–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Jordan MB, et al. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735–43.CrossRefPubMedGoogle Scholar
  22. 22.
    Das R, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016;127(13):1666–75.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Maschalidi S, et al. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood. 2016;128(1):60–71.CrossRefPubMedGoogle Scholar
  24. 24.
    Terrell CE, Jordan MB. Mixed hematopoietic or T-cell chimerism above a minimal threshold restores perforin-dependent immune regulation in perforin-deficient mice. Blood. 2013;122(15):2618–21.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Rivat C, et al. SAP gene transfer restores cellular and humoral immune function in a murine model of X-linked lymphoproliferative disease. Blood. 2013;121(7):1073–6.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Tiwari S, et al. High level of perforin expression is required for effective correction of hemophagocytic lymphohistiocytosis. Hum Gene Ther. 2016.Google Scholar
  27. 27.
    Carmo M, et al. Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency. Mol Ther. 2015;23(4):737–45.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Eapen M, et al. Hematopoietic cell transplantation for Chediak-Higashi syndrome. Bone Marrow Transplant. 2007;39(7):411–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Yoon HS, et al. The outcome of hematopoietic stem cell transplantation in Korean children with hemophagocytic lymphohistiocytosis. Pediatr Transplant. 2010;14(6):735–40.CrossRefPubMedGoogle Scholar
  30. 30.
    Cooper N, et al. The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Bone Marrow Transplant. 2008;42(Suppl 2):S47–50.CrossRefPubMedGoogle Scholar
  31. 31.
    Marsh RA, et al. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood. 2013;121(6):877–83.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Marsh RA, et al. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1. Biol Blood Marrow Transplant. 2014;20(10):1641–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Pediatrics, University of WashingtonSeattleUSA
  2. 2.Divisions of Immunobiology, and Bone Marrow Transplantation and Immune Deficiency, Department of PediatricsCincinnati Children’s Hospital Medical Center, University of CincinnatiCincinnatiUSA

Personalised recommendations